Evaluation of the cost-utility of orlistat (Xenical) in the United Kingdom

被引：1
|
作者：
McEwan, P
Jones, M
Farina, C
Currie, CJ
机构：
[1] Univ Wales Coll Cardiff, Cardiff, S Glam, Wales
[2] Roche Prod Ltd, Welwyn Garden City, Herts, England
[3] Cardiff Res Consortium, Cardiff, S Glam, Wales
来源：
VALUE IN HEALTH | 2004年 / 7卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)65900-1
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：721 / 721
页数：1
相关论文
共 50 条
  • [1] A cost-utility analysis of orlistat (Xenical) in the treatment of diabetic patients with morbid obesity and additional CVD risk in Norway
    Sverre, J. M.
    Kristensen, F. K. O.
    Holm, L. B.
    Nyhus, K.
    VALUE IN HEALTH, 2006, 9 (06) : A232 - A232
  • [2] A COST-UTILITY ANALYSIS OF LIGHTERLIFE TOTAL AS A TREATMENT FOR OBESITY IN THE UNITED KINGDOM
    Lewis, L.
    Taylor, M.
    VALUE IN HEALTH, 2013, 16 (07) : A385 - A385
  • [3] COST-UTILITY EVALUATION COMPARING DISEASE PROGRESSION IN MODERATE VERSUS SEVERE PSORIASIS IN ADULTS IN THE UNITED KINGDOM
    Szewczenko, I
    Jackson, D.
    Thompson, P.
    Betts, A.
    VALUE IN HEALTH, 2020, 23 : S595 - S595
  • [4] TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS - A COST-UTILITY MODEL FOR THE UNITED KINGDOM
    Chang, S.
    Sawyer, L.
    Dejonckheere, F.
    van Suijlekom-Smit, L. W.
    Anink, J.
    Diamantopoulos, A.
    VALUE IN HEALTH, 2013, 16 (07) : A564 - A564
  • [5] The cost-utility of calcipotriol/bethamethasone (Dovobet) ointment in the treatment of psoriasis vulgaris in the United Kingdom
    Noerregaard, J
    Lowson, D
    VALUE IN HEALTH, 2003, 6 (06) : 785 - 785
  • [6] Influenza treatment with neuraminidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom
    Sander B.
    Gyldmark M.
    Hayden F.G.
    Morris J.
    Mueller E.
    Bergemann R.
    The European Journal of Health Economics, 2005, 6 (3) : 244 - 252
  • [7] Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom
    Young, A. H.
    Evitt, L.
    Brignone, M.
    Diamand, F.
    Atsou, K.
    Campbell, R.
    Cure, S.
    Danchenko, N.
    JOURNAL OF AFFECTIVE DISORDERS, 2017, 218 : 291 - 298
  • [8] The cost-utility of exelon patch in the management of patients with moderate Alzheimer's disease in the United Kingdom
    Brennan, A.
    Nagy, B.
    Brandtmuller, A.
    Thomas, S. K.
    Sullivan, S. D.
    Akehurst, R.
    VALUE IN HEALTH, 2007, 10 (06) : A384 - A384
  • [9] Cost-utility analysis of normothermic liver perfusion with the OrganOxmetracompared to static cold storage in the United Kingdom
    Javanbakht, Mehdi
    Mashayekhi, Atefeh
    Trevor, Miranda
    Branagan-Harris, Michael
    Atkinson, Jowan
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (11) : 1284 - 1292
  • [10] TOCILIZUMAB IN METHOTREXATE-INTOLERANT OR CONTRAINDICATED PATIENTS-A COST-UTILITY MODEL FOR THE UNITED KINGDOM
    Harland, Dave
    Gibbons, Carl
    Pang, Hok
    Huertas, Catherine
    Diamantopoulos, Alex
    Dejonckheere, Fred
    RHEUMATOLOGY, 2013, 52 : 84 - 84
12345